{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:25:47Z","timestamp":1791307547494,"version":"4.3.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jhep.2014.08.033","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T21:13:14Z","timestamp":1409346794000},"page":"1407-1417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":272,"title":["Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management"],"prefix":"10.1016","volume":"61","author":[{"given":"Ming-Ling","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fan","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.08.033_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.033_b0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","article-title":"Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy","volume":"18","author":"Liaw","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0016-5085(83)80114-0","article-title":"Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis","volume":"84","author":"Liaw","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0168-8278(90)90069-4","article-title":"Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology","volume":"10","author":"Lok","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0030","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0035","first-page":"143","article-title":"Pathogenesis and clinical significance of spontaneous exacerbation and remissions in chronic HBV infection","volume":"3","author":"Liaw","year":"1997","journal-title":"Viral Hepat Rev"},{"key":"10.1016\/j.jhep.2014.08.033_b0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0168-8278(85)80050-7","article-title":"Acute exacerbation in hepatitis B e antigen-positive chronic type B hepatitis: a clinicopathological study","volume":"1","author":"Liaw","year":"1985","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.1840070106","article-title":"Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody positive patients","volume":"7","author":"Liaw","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0050","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0055","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0168-8278(03)00319-2","article-title":"Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview","volume":"39","author":"Bonino","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0060","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0016-5085(85)90566-9","article-title":"Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis","volume":"89","author":"Sheen","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/hep.1840090319","article-title":"The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers","volume":"9","author":"Chu","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0676.1990.tb00455.x","article-title":"Acute exacerbation in patients with liver cirrhosis: a clinicopathological study","volume":"10","author":"Liaw","year":"1990","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2014.08.033_b0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep.1840070326","article-title":"IgM anti-HBc in anti-HBe positive chronic type B hepatitis with acute exacerbations","volume":"7","author":"Koike","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0676.1986.tb00279.x","article-title":"Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma","volume":"6","author":"Liaw","year":"1986","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2014.08.033_b0085","unstructured":"Peng CY, Chen SH, Chu CM, Sheen IS, Tai DI, Tsai SL, et al. Oval cell activation during acute exacerbation in patients with chronic hepatitis type B or C. Asian Pacific Association for the Study of the Liver Meeting 2002;145\u2013148."},{"key":"10.1016\/j.jhep.2014.08.033_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840070102","article-title":"Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis","volume":"7","author":"Liaw","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0676.1988.tb00998.x","article-title":"Changes of serum HBV DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis","volume":"8","author":"Liaw","year":"1988","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2014.08.033_b0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/gast.2003.50003","article-title":"A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation","volume":"124","author":"Liu","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0105","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0016-5085(93)90960-K","article-title":"Serology of acute exacerbation in chronic hepatitis B virus infection","volume":"105","author":"Maruyama","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0016-5085(87)90863-8","article-title":"Intrahepatic distribution of HBsAg and HBcAg in chronic hepatitis B virus infection: hepatocyte with cytoplasmic\/membranous HBcAg as a possible target for immune hepatocytolysis","volume":"92","author":"Chu","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.1840080358","article-title":"HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis","volume":"8","author":"Chu","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1172\/JCI115590","article-title":"Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion","volume":"89","author":"Tsai","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.08.033_b0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/00365529209011173","article-title":"Hepatitis B core antigen-specific interferon gamma production of peripheral blood mononuclear cells during acute exacerbation of chronic hepatitis B","volume":"27","author":"Takehara","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.08.033_b0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2249.1995.tb03720.x","article-title":"The expression of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B","volume":"100","author":"Fukuda","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2014.08.033_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hep.23273","article-title":"Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B","volume":"51","author":"Zhang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11373-006-9129-z","article-title":"HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection","volume":"14","author":"Feng","year":"2007","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jhep.2014.08.033_b0145","first-page":"183","article-title":"Acute exacerbations of chronic hepatitis B are accompanied by decline of core antigen-specific regulatory T-cell frequencies: implications for successful anti-HBV treatments","volume":"7","author":"Tsai","year":"2007","journal-title":"Hepat Monthly"},{"key":"10.1016\/j.jhep.2014.08.033_b0150","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.humimm.2010.11.001","article-title":"Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation","volume":"72","author":"Koay","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jhep.2014.08.033_b0155","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.1103139","article-title":"IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection","volume":"189","author":"Das","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.08.033_b0160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20061287","article-title":"Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage","volume":"204","author":"Dunn","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0165","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-230X-12-109","article-title":"Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B","volume":"12","author":"Wenjin","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2014.08.033_b0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2014.08.033_b0180","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1111\/j.1440-1746.1997.tb00520.x","article-title":"Current trends in therapy for chronic viral hepatitis","volume":"12","author":"Liaw","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0185","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gut.52.3.416","article-title":"A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy","volume":"52","author":"Yuen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.08.033_b0190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0195","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2005.03.018","volume":"43","author":"Chu","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2893.2006.00799.x","article-title":"Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion","volume":"14","author":"Yuen","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.033_b0205","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","article-title":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B","volume":"8","author":"Jeng","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","article-title":"Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?","volume":"34","author":"Nair","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0225","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1172\/JCI119498","article-title":"Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B","volume":"99","author":"Rossol","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.08.033_b0230","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0235","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0240","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.08.033_b0245","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.033_b0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0255","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.08.033_b0260","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.08.033_b0265","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0270","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0275","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0280","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1053\/jhep.2000.9717","article-title":"Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B","volume":"32","author":"Liaw","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0290","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0295","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","article-title":"A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B","volume":"44","author":"Zeng","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0305","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0310","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0315","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0320","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0325","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0330","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0335","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.22419","article-title":"Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion","volume":"48","author":"Evans","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0340","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510300221","article-title":"Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy","volume":"30","author":"Liaw","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0345","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/135965350400900208","article-title":"No benefit to continue lamivudine therapy after emergence of YMDD mutations","volume":"9","author":"Liaw","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.08.033_b0350","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0355","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","article-title":"Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia","volume":"51","author":"Liaw","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0360","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/jhep.2000.16333","article-title":"Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy","volume":"32","author":"Honkoop","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0365","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.51.4.597","article-title":"Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B","volume":"51","author":"Lim","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.08.033_b0370","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0375","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/j.1365-2893.2011.01448.x","article-title":"Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B","volume":"18","author":"Zhang","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.033_b0380","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0385","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"The determinants for sustained HBeAg response to lamivudine therapy","volume":"38","author":"Chien","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0390","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","article-title":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0395","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0400","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni1317","article-title":"Mother\u2019s little helpers: mechanisms of maternal-fetal tolerance","volume":"7","author":"Trowsdale","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2014.08.033_b0405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2007.00894.x","article-title":"Exacerbation of chronic hepatitis B infection after delivery","volume":"15","author":"ter Borg","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.033_b0410","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/apt.12726","article-title":"Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare","volume":"39","author":"Nguyen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.08.033_b0415","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12072-008-9063-4","article-title":"Chronic hepatitis B virus (HBV) infection in pregnancy","volume":"2","author":"Tan","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2014.08.033_b0420","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/421386","article-title":"Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART","volume":"39","author":"Drake","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.033_b0425","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/597276","article-title":"Immunopathogenesis of hepatic flare in HIV\/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy","volume":"199","author":"Crane","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.033_b0430","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0016-5085(90)90846-S","article-title":"Isoniazid-rifampin-induced hepatitis in hepatitis B carriers","volume":"98","author":"Wu","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0435","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.033_b0440","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0445","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.033_b0450","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0455","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.08.033_b0460","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0465","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2014.08.033_b0470","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.033_b0475","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2014.08.033_b0480","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2011.01.003","article-title":"Viral hepatitis in solid organ transplantation other than liver","volume":"55","author":"Vallet-Pichard","year":"2011","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814006205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814006205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T03:14:09Z","timestamp":1717298049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814006205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0168827814006205"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.033","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}